Lupe Duarte

Learn More
Bendamustine is a multifunctional alkylating agent with single agent activity in myeloma. We designed the current phase 1/2 trial to determine the maximum tolerated doses (MTD) of bendamustine that can be safely combined with lenalidomide and dexamethasone and to assess the safety and efficacy of the combination. Patients with relapsed MM following at least(More)
P ROGNOSIS in aplastic anemia has improved since the introduction of testosterone therapy.1 This androgenic hormone has proved very useful in the treatment of children with congenital and acquired aplastic anemia,1-5 but appears to be less effective in adults with the same disorder.#{176} Oxymetho1one79 and other related steroids4’1015 have recently been(More)
We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous stem cell transplantation (ASCT) in patients with multiple myeloma. Within 4 to 8 weeks of ASCT, patients received weekly bortezomib and(More)
O UR PREVIOUS OBSERVATIONS have shown that intraperitoneal administration of autohemolysates accelerates the recovery from anemia in bled dogs.13 On the basis of this and other experimental data4#{176} we reconsidered the hypothesis7’8 that red cell constituents have an erythropoietic stimulatory effect.1’6 However, it has been suggested that the above(More)
  • 1